For healthcare, pharma and life sciences
Content marketing for healthcare, pharma and life sciences.
Your people already write more than almost anyone. The trouble is where: in journals, behind paywalls, for other researchers. Findwell takes the same expertise and puts it where a procurement lead, a clinician or an investor is actually looking.
- A hub, and the team that fills itSoftware on your domain with a page per specialist, written and taken through your own review
- Specialists who get foundRanking on Google, quoted in the trade and science press, named in AI answers
- From £1,000Per specialist a month, six month minimum, no setup fee
What Findwell is
A content platform, and the agency that translates your experts.
Two things that are usually bought separately, and that only work together. Here is the whole proposition in one line.
The work
An agency that translates the science
We interview your clinicians and scientists, write in their voice, prepare it for medical and regulatory review, and pitch it out.
The place
A platform of your own to hold it
A hub on your subdomain with a page per specialist, structured so search and AI can read it.
Findwell
The platform, with the people who feed it
Live in about two weeks, on an hour a month from each specialist.
What it is
A page for every specialist, in language the buyer reads.
On a subdomain of your own site. What they work on, what the evidence actually shows and what it means in practice, structured so search engines and answer engines can attribute it to a named expert.
Pick one to find it on the page
And the two questions review will ask
Plain English without losing the qualification that makes the claim true. Every statement referenced, so a reviewer is checking sources rather than rewriting sentences.
Scope agreed with medical and regulatory before a word is written, and nothing published that has not been signed. We work to your review cycle rather than asking it to move.
Where we secure coverage for health and life sciences clients
What you get
Everything a specialist needs, made for them.
One conversation with a specialist turns into all of this. We make it, we take it through review, we place it, and every piece lands back on their own page.
Shapes everything below
Published, then on the hub
Lives on the hub
Posted, then links to the hub
Sent, then kept on the hub
Cut, then hosted on the hub
See what your specialists would rank for.
A thirty-minute walkthrough on your own firm. We will show you where your specialists sit today, and what the first quarter would produce.
How it works
One hour a month. We do the rest.
The whole commitment from each specialist, in one picture.
That is the whole ask. You talk, your reviewers sign, and everything in between is ours.
You talk
Recorded, with an editor who knows the field well enough to push back, and to notice when a qualification is doing real work.
Review signs
We draft in their voice, reference every claim, and submit it to medical and regulatory review. Your reviewers sign. Specialists approve rather than write.
We do the rest
Published on your hub, pitched to the health and science desks, then cut for LinkedIn, the briefing and video.
A worked example, not a client
What a year looks like for one specialist.
The plan we would put in front of a regulatory lead in week one, quarter by quarter. No firm has to imagine what the retainer produces.
The specialist
Nine approvals and forty citations, and nothing a customer could read without a subscription.
The niche
When software becomes a regulated medical deviceNarrow enough that one person can own it, broad enough that founders, clinical safety officers and procurement teams are all searching it at once.
Why that one
2,100searches a month across the cluster, and almost no expert-level pages answering any of it
Once, before anything is published
Content strategy
Agreed with Aisha and with BD before a word is written, so nobody is arguing about scope in month three- Which question Aisha owns, and how narrow to go. Regulatory affairs is far too broad to win, when software becomes a device is not
- The questions worth answering, ranked by what buyers search rather than by what we publish on
- What can be said non-promotionally, agreed with medical and regulatory on day one
Biography and specialist page
Not the publication list and not the conference bio, both of which are written for other researchers- The areas Aisha can talk about, and the programmes still confidential
- What Aisha is known for, in the words a procurement lead would use
- Structured so search and answer engines can attribute it to a named expert with a real record
Social refresh
It is the first thing a distributor or a clinician checks, and it currently lists conferences from 2019- Headline and about section rewritten around the niche rather than the firm
- Featured section pointing back at the hub
- Banner and profile consistent with the specialist page
Live in about two weeks, with no IT project and nothing for your web team to do. Nothing is published yet, and nothing has been near risk and compliance, which is deliberate. We agree what Aisha is claiming to be expert in before anyone has to approve a word of it.
Every month
3 insight extractions, one a month
Forty minutes, recorded, with an editor who knows the practice well enough to push back. Everything below comes out of it- The argument Aisha makes to every founder who has already shipped
- What the guidance changed in practice rather than on paper
- The claim Aisha keeps seeing that makes a product regulated
3 newsletters, one a month
Written from the interviews and sent to Aisha’s own contacts, then republished on the hub so the cluster and the client list grow together- When your software becomes a medical device
- The three claims that turn wellness into a regulated product
- Classification, and where people consistently get it wrong
1 media piece: an op-ed
We start where Aisha controls the argument, so the first one is placed on our own timing rather than chased into a news cycle- “Most digital health companies find out too late”, in Med-Tech Innovation
5 video clips filmed
One sitting on an interview day, so the whole year of video costs no extra specialist time- The three claims that make you a regulated product
- What classification actually means, in plain English
- Wellness or medical device, and how to tell
- Can you self-certify, and what to check first
- What happens when you get classification wrong
LinkedIn, as it comes
Posted off the back of each piece and whenever the news gives Aisha a reason, rather than to a schedule nobody believes in- A post for every piece we publish
- A reaction on the days the MHRA publishes new guidance
- Comment on a guidance change while people are still reading it
Indexed within the month. Nothing ranking yet, and anyone promising otherwise on a new hub is guessing. What usually happens first is that your own sales team starts sending it. A clear regulatory explainer answers the question that stalls almost every first call.
Every month
3 insight extractions, one a month
The conversations keep going. New matters, new rules, whatever Aisha is arguing that month- What the new guidance has done to timelines a year on
- Where submissions are stalling, and what that looks like early
- The AI question Aisha gets asked most
3 newsletters, one a month
Each republished on the hub. Six pieces in, and the cluster starts to join up rather than sit as separate posts- Clinical evaluation for software, without a trial
- What the MHRA actually asks to see
- Post-market surveillance nobody budgets for
1 media piece: an interview
Pitched off the back of a live story, so Aisha is the name the desk already has when it runs. A harder format to earn than an op-ed- Interview with Digital Health on what the guidance has done to approval timelines
Video running
Published from the quarter one sitting, one every fortnight or so, cut back to a single question each- One clip a fortnight, on the hub and on LinkedIn
- Each one answering one question and nothing else
- Subtitled, because most of it is watched on mute
LinkedIn, as it comes
Posted off the back of each piece and whenever the news gives Aisha a reason- A post for every piece we publish
- Reaction on the days the numbers or a judgment land
- The occasional short answer to a question Aisha keeps being asked
The first enquiries tend to come from advisers rather than directors. The first enquiries come from distributors and procurement rather than clinicians. They are the people who have to be satisfied before anybody else is even asked.
Every month
3 insight extractions, one a month
Filmed on one of these days, so the second sitting of clips costs no extra specialist time- What a notified body can and cannot ask for
- The timeline conversation boards have too late
- What the approval data actually shows, under the headline
3 newsletters, one a month
Each republished on the hub. Nine pieces in, and the niche is most of the way covered- AI as a medical device, and what actually changes
- What a notified body actually reviews
- Reading the MHRA guidance properly
1 media piece: broadcast
Pitched in response to breaking news, on a story where a reporter needs a name today. This is the slot the first two quarters earn and the one no firm can buy- Radio or podcast comment on the health technology story running that week
5 more clips filmed
The second sitting, six months on, to carry the rest of the year- AI features, and what they do to your risk class
- Notified body review, in plain English
- The approval data, and what it really shows
- Post-market surveillance on a realistic budget
- Talking to your board about approval timelines
LinkedIn, as it comes
By now the posts are getting picked up by journalists as often as by clients- A post for every piece we publish
- A same-day reaction when the MHRA updates its guidance
- The clips, one at a time, as they come out
Journalists start calling rather than being pitched, usually the week new guidance lands. And when a founder asks an assistant whether their product is regulated, Aisha’s is a name that comes back.
Every month
3 insight extractions, one a month
The last three of the year, and the one where we ask what Aisha wants to own next- What changed this year in UK approval
- Where Aisha thinks the bottlenecks land next year
- The question Aisha wants to be known for in year two
3 newsletters, one a month
Including the annual guide, which pulls the whole year onto one page and becomes the piece that ranks hardest- Software as a medical device, the annual guide
- What changed this year in UK approval, and what did not
- Where approvals bottleneck next year, class by class
1 media piece: a year-ahead op-ed
Placed as the year turns, when every desk wants a forecast and almost nobody will commit to one. By now Aisha is a name the City desk recognises- “The health products that will not reach patients next year”, pitched to a national
Video running
From the quarter three sitting, still one a fortnight- One clip a fortnight, on the hub and on LinkedIn
- The annual guide cut down into a two-minute explainer
LinkedIn, as it comes
Posted off the back of each piece, and the year-ahead piece will do more than anything else Aisha has published- A post for every piece we publish
- The year-ahead argument, in Aisha’s own words, ahead of the op-ed running
The cluster answers the whole question rather than one part of it. That is the point at which it starts pulling procurement and partnership conversations rather than traffic, from buyers who arrive already knowing the answer.
What that adds up to
12 hours
Of the specialist’s time across the year. Twelve insight extractions, one a month, and a read of the drafts. The filming happens on two of those same days, so it costs nothing extra.
Across the sector
The model is the same. What we publish is not.
A regulatory lead at a device company and a medical affairs lead at a pharma company are read by completely different people, and neither is read by the other.
Device buyers are searching the regulation, not the product
We work with regulatory and clinical leads at device companies, supporting them with classification explainers, evidence guidance, approval commentary and the notes procurement teams keep on file.
Nobody buys a device on a brochure any more. A trust or a distributor is trying to work out whether it will clear, whether the evidence holds and who has done this before. Whether it is classification, clinical evaluation or a product that has quietly become regulated, your specialist is the one who has already explained it in public.
The team behind it
You are hiring people, not software.
Findwell is a product of Profile, an award-winning thought leadership and PR agency. So is the team.
“This is the only sector I work in where the expertise is already written down. It is in journals, behind paywalls, in a format built for reviewers rather than readers, and the person who needs it is a procurement lead with twenty minutes. Nobody has to become a writer here. Somebody just has to sit with the expert and ask what it means, then publish the answer where the question is actually being asked.”
Jordan GreenawayFounder, Profile
Questions
What firms ask before they start.
+How much does content marketing for healthcare and life sciences cost?
+Our people already publish in journals. Why is this different?
+How does this work with the ABPI Code?
+Can we talk about a product that is not approved yet?
+Is this SEO, AEO, GEO, PR or thought leadership?
+Who writes it, and how much specialist time does it take?
+How long before our specialists rank for these questions?
+What happens to the content if a specialist leaves?
+Can we start with a couple of people rather than the whole company?
+Why not just hire someone to do this in-house?
See what your specialists would rank for.
A thirty-minute walkthrough, on your own firm, of where your specialists sit today and what it would take to move them.